Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Can drug regimen changes prevent seizures in patients with apparently drug-resistant epilepsy?

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kwan P and Brodie MJ (2000) Early identification of refractory epilepsy. N Engl J Med 342: 314–319

    Article  CAS  Google Scholar 

  2. Selwa LM et al. (2003) Long-term outcome of nonsurgical candidates with medically refractory localization-related epilepsy. Epilepsia 44: 1568–1572

    Article  Google Scholar 

  3. Sillanpaa M and Schmidt D (2006) Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 129: 617–624

    Article  Google Scholar 

  4. Berg AT et al. (2006) How long does it take for epilepsy to become intractable? A prospective investigation. Ann Neurol 60: 73–79

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jim Casey, Editorial Assistant, Nature Clinical Practice.

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

In the last 12 months, Dr French has received <US$10,000 in speaking/consulting fees from Eisai, Valeant/Schwarz, Spherics, Johnson & Johnson and Astra-Zeneca.

Dr French has also provided consulting services to UCB, Marinus, Johnson & Johnson, Teva, Schwarz, Valeant, Shire, Intranasal, Jazz and Eisai. She serves as chair of the data safety monitoring board for a study sponsored by Johnson & Johnson. Over the past year, Dr French has provided these services as an agent of the nonprofit organization Epilepsy Therapy Development Project. The Epilepsy Therapy Development Project contributes a fixed amount to Dr French's salary for this and other services, including chairing their scientific advisory board and grant review. The amount of contribution is not linked to the amount of consulting activity.

Twenty percent of Dr French's salary derives from work on behalf of FACES (Finding A Cure for Epilepsy and Seizures), a nonprofit organization.

Dr French has been site principal investigator on studies of brivaracetam (UCB), RWJ-333369 (Johnson & Johnson), selectracetam (UCB), talampanel (Ivax), lacosamide (Schwarz Pharma), retigabine (Valeant), rufinamide (Eisai) and the thalamic stimulator (Medtronics). She is national principal investigator for an ongoing study of rufinamide, retigabine and the vagus nerve stimulator (Cyberonics).

Rights and permissions

Reprints and permissions

About this article

Cite this article

French, J. Can drug regimen changes prevent seizures in patients with apparently drug-resistant epilepsy?. Nat Rev Neurol 3, 364–365 (2007). https://doi.org/10.1038/ncpneuro0500

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0500

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing